Teva releases generic Afinitor
Teva is introducing its generic Afinitor (everolimus tablets).
The generic of Novartis' branded product is indicated to treat advanced renal cell carcinoma after the failure of other treatments, as well as to treat renal angiomyolipoma and tuberous sclerosis complex that doesn't require immediate surgery.
Teva's generic is available in dosage strengths of 2.5 mg, 5 mg and 7.5 mg, and comes in blister packs of 28 tablets.
Everolimus tablets had a market value of roughly $435 million in the 12 months ending April 2020, according to IQVIA.